Effects of etiroxate on low density and high density lipoproteins in hypercholesterolemic patients.

Abstract

Six female patients with a primary hyperlipoproteinemia type IIa received 40 mg/day etiroxate for 2 months. Serum lipids, low density and high density lipoprotein cholesterol, the apolipoproteins B and A-I, and cholesterol and apolipoprotein A-I in ultracentrifuged HDL2 and HDL3 were analysed before and after the treatment. Etiroxate caused a significant reduction in serum cholesterol, LDL-cholesterol, and serum apolipoprotein B. Concerning the HDL, there was a significant decrease in HDL-cholesterol. The analysis of HDL subfractions revealed a uniform fall in HDL2-cholesterol and HDL2-apolipoprotein A-I. It is concluded that detailed information about lipoproteins leads to a better understanding of the relationships between drug treatment and the possible prevention of atherosclerotic diseases.

• Authors: P Weisweiler, P Schwandt
• Journal: Atherosclerosis (Atherosclerosis) Vol. 39 Issue 1 Pg. 45-9 (Apr 1981) ISSN: 0021-9150 [Print] Ireland
• PMID: 7247989 (Publication Type: Journal Article)

Chemical References

• Apolipoproteins
• Lipoproteins, HDL
• Lipoproteins, LDL
• Triglycerides
• etiroxate
• Cholesterol
• Thyroxine

Topics

• Adult
• Apolipoproteins (blood)
• Cholesterol (blood)
• Female
• Humans
• Hyperlipoproteinemia Type II (blood, drug therapy)
• Lipoproteins, HDL (blood)
• Lipoproteins, LDL (blood)
• Middle Aged
• Thyroxine (analogs & derivatives, therapeutic use)
• Triglycerides (blood)